<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542994</url>
  </required_header>
  <id_info>
    <org_study_id>EDP1066-001</org_study_id>
    <secondary_id>2017-004337-90</secondary_id>
    <nct_id>NCT03542994</nct_id>
  </id_info>
  <brief_title>A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis</brief_title>
  <official_title>A Phase 1a/1b Randomized Double-blind Placebo-controlled Single and Multiple Ascending Dose Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evelo Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evelo Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evelo will investigate the safety and tolerability of EDP1066 and its potential to be a
      medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and
      atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled clinical study with dose
      escalations to assess safety, tolerability, and pharmacodynamic effect of EDP1066. Since this
      clinical study is the first study in humans, the participants will be healthy volunteers or
      subjects with mild to moderate psoriasis or atopic dermatitis who are otherwise well.
      Investigation of EDP1066 in this patient population provides an opportunity to gain
      pharmacodynamic information using a range of tissue biopsies and composite clinical
      endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study is a double-blind dose escalation cohort study in healthy volunteers and participants with either mild to moderate psoriasis or mild to moderate atopic dermatitis. The study consists of 9 cohorts and will test doses of EDP1066 versus placebo. The safety and tolerability of EDP1066 will be tested in participants with psoriasis and atopic dermatitis alongside pharmacodynamic effects on the systemic immune system and observation of any clinical effects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability measured through Adverse Events (AEs)</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>Number of participants with AEs by seriousness and relationship to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability measured through lab measurements</measure>
    <time_frame>Day 0 to Day 60</time_frame>
    <description>Number of participants with clinically significant change from baseline (Day 0) in laboratory values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability measured through ECG</measure>
    <time_frame>Day 0 to Day 60</time_frame>
    <description>Number of participants with clinically relevant changes from baseline (Day 0) ECG parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability measured through physical examination</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>Physical examination of stool samples based on the Bristol Stool Scale (Types 3 and 4 are ideal stool):
Type 1: Separate hard lumps, like nuts (hard to pass); Type 2: Sausage-shaped, but lumpy; Type 3: Like a sausage but with cracks on its surface; Type 4: Like a sausage or snake, smooth and soft; Type 5: Soft blobs with clear cut edges (easy to pass); Type 6: Fluffy pieces with ragged edges, a mushy stool; Type 7: Watery, no solid pieces, entirely liquid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GI safety measurement through biomarker analysis</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>GI safety measurement through fecal calprotectin analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement in subjects with mild to moderate psoriasis</measure>
    <time_frame>Day 0 to Day 60</time_frame>
    <description>Change from baseline (Day 0) Psoriasis-area-and-severity index score (PASI) in response to EDP1066, measured on a scale of 0 to 6 (where 0 is most favorable and 6 is least favorable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement in subjects with mild to moderate atopic dermatitis</measure>
    <time_frame>Day 0 to Day 60</time_frame>
    <description>Change from baseline (Day 0) Eczema-area-and-severity index score (EASI) in response to EDP1066, measured on a scale of 0 to 6 (where 0 is most favorable and 6 is least favorable).</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Psoriasis</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 66 mg, capsule, once daily, 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>12 subjects with mild to moderate psoriasis; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
Dose=up to a maximum of 660 mg, capsule, once daily, 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>up to 24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3g, capsule, once daily, 29 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EDP1066</intervention_name>
    <description>EDP1066 is an orally administered monoclonal microbial</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General:

          -  Participant has a body mass index of ≥ 18 kg/m2 to ≤ 35 kg/m2 at Screening.

        Healthy Volunteers:

          -  Participants who are overtly healthy as determined by medical evaluation including
             medical history, physical examination, laboratory tests, and cardiac monitoring.

        Mild to moderate psoriasis:

          1. Participant has had a confirmed diagnosis of mild to moderate plaque-type psoriasis
             for at least 6 months involving ≤ 5% of body surface area (BSA) (excluding the scalp).

          2. Participant has a minimum of 2 psoriatic lesions with at least 1 plaque in a site
             suitable for biopsy.

        Mild to moderate atopic dermatitis:

          1. Mild to moderate atopic dermatitis with a minimum of 3% to a maximum of 15% BSA
             involvement.

          2. Participant has had a confirmed diagnosis of mild to moderate atopic dermatitis for at
             least 6 months IGA score of 2 or 3.

          3. Participant has a minimum of 2 atopic dermatitis lesions with at least 1 in a site
             suitable for biopsy.

        Exclusion Criteria:

          1. Female participant who is pregnant, or plans to become pregnant during the study, or
             breastfeeding, or sexually active with childbearing potential who is not using a
             medically accepted birth control method.

          2. Participant has received live attenuated vaccination within 6 weeks prior to Screening
             or intends to have such a vaccination during the course of the study.

          3. Participant has received any investigational drug or experimental procedure within 90
             days or 5 half-lives, whichever is longer, prior to study intervention administration.

          4. Participant requires treatment with an anti-inflammatory drug during the study period.
             Paracetamol will be permitted for use as an antipyretic and/or analgesic (maximum of 2
             grams/day in any 24 hour period).

          5. Participant has an active infection (e.g. sepsis, pneumonia, abscess) or has had an
             infection requiring antibiotic treatment within 6 weeks prior to Investigational
             Medicinal Product (IMP) administration. When in doubt, the investigator should confer
             with the Sponsor study physician.

          6. Participant has renal or liver impairment, defined as:

             a. For healthy volunteers: i. For women, serum creatinine level ≥ 125 μmol/L; for men,
             ≥ 135 μmol/L, or ii. Alanine aminotransferase (ALT) and aspartate aminotransferase
             (AST) ≥ 1.5 x upper limit of normal (ULN), or iii. Alkaline phosphatase (ALP) and/or
             bilirubin &gt; 1.5 x ULN b. For participants with mild to moderate atopic dermatitis or
             psoriasis: i. For women, serum creatinine level ≥ 125 μmol/L; for men, ≥ 135 μmol/L,
             or ii. ALT or AST &gt; 2 x ULN and/or bilirubin &gt; 1.5 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duncan McHale, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Evelo Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daryl Bendel, MBChB, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Surrey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Fiore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aliya Asher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAC Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Fitzgerald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Liverpool Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Surrey Clinical Research Center</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 3DL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Cannock</city>
        <zip>WS11 0BN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Clinical Research Unit</name>
      <address>
        <city>Liverpool</city>
        <zip>L78XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit Ltd., The Langley Building, Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS17 6EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

